James F. Callahan - Concepedia

Author

James F. Callahan

Also Known As

Callahan, J.F., J Callahan, J F Callahan, J. F. CALLAHAN, J. F. Callahan, J.F. Callahan, James F. Callahan, James Callahan, James F. Callahan

Publications

5.8K

Citations

H-Index

109

Concepts

All Affiliations

GlaxoSmithKline (United States)New Frontier GlaxoSmithKline (United Kingdom)South College

About

James F. Callahan is an author at GlaxoSmithKline (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	28	2.4K
2	Natural Sciences	13	16	1.3K
3	Health Sciences	6	6	437
4	Engineering	2	2	28
5	Arts	1	1	15

James F. Callahan

Publications

5.7K

Citations

H-Index

Page 1

	Year	Citations
SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7 Gareth J. Inman, Francisco José Nicolás, James F. Callahan, Molecular Pharmacology	2002	1.6K
Inhibition of Transforming Growth Factor (TGF)-β1–Induced Extracellular Matrix with a Novel Inhibitor of the TGF-β Type I Receptor Kinase Activity: SB-431542 Nicholas J. Laping, Eugene T. Grygielko, Anil Mathur, Molecular Pharmacology	2002	647
Identification of Novel Inhibitors of the Transforming Growth Factor β1 (TGF-β1) Type 1 Receptor (ALK5) James F. Callahan, Joelle L. Burgess, James A. Fornwald, Journal of Medicinal Chemistry Drug TargetPharmacotherapyCell GrowthTumor BiologyGrowth Factor Beta1	2002	309
Attenuation of Murine Collagen-Induced Arthritis by a Novel, Potent, Selective Small Molecule Inhibitor of IκB Kinase 2, TPCA-1 (2-[(Aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), Occurs via Reduction of Proinflammatory Cytokines and Antigen-Induced T Cell Proliferation Patricia L. Podolin, James F. Callahan, Brian Bolognese, Journal of Pharmacology and Experimental Therapeutics	2004	296
Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein–Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery Thomas G. Davies, William E. Wixted, Joseph E. Coyle, Journal of Medicinal Chemistry Molecular BiologyChemical BiologyRedox BiologyOxidative StressMonoacidic Inhibitors	2016	295
Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats Maxine Gowen, George B. Stroup, Robert A. Dodds, Journal of Clinical Investigation Parathyroid GlandHormone SecretionNps 2143OsteoporosisOrthopaedic Surgery	2000	274
Structure of the BTB Domain of Keap1 and Its Interaction with the Triterpenoid Antagonist CDDO Anne Cleasby, Jeff Yon, Philip J. Day, PLoS ONE Molecular BiologyBtb DomainChemical BiologyRedox BiologyProtein Keap1	2014	250
Discovering Drugs with DNA‐Encoded Library Technology: From Concept to Clinic with an Inhibitor of Soluble Epoxide Hydrolase Svetlana Belyanskaya, Yun Ding, James F. Callahan, ChemBioChem Molecular BiologyChemical BiologyEncoded-library TechnologySoluble Epoxide HydrolaseMedicinal Chemistry	2017	194
Keap Calm, and Carry on Covalently A. James Wilson, Jeffrey K. Kerns, James F. Callahan, Journal of Medicinal Chemistry	2013	167
Discovery of Orally Active Nonpeptide Vitronectin Receptor Antagonists Based on a 2-Benzazepine Gly-Asp Mimetic William H. Miller, Doreen Alberts, Pradip K. Bhatnagar, Journal of Medicinal Chemistry PharmacotherapyExperimental PharmacologyPharmacodynamic ModelingTranslational PharmacologyPre-clinical Pharmacology	1999	116

Page 1